Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation

被引:0
|
作者
Lenhoff, Stig [1 ]
Hjorth, Martin [2 ]
Turesson, Ingemar [3 ]
Westin, Jan [1 ]
Gimsing, Peter [4 ]
Wisloff, Finn [5 ]
Ahlberg, Lucia [6 ]
Carlson, Kristina [7 ]
Christiansen, Ilse [8 ]
Dahl, Inger Marie [9 ]
Forsberg, Karin [10 ]
Brinch, Lorentz
Hammerstrom, Jens [11 ]
Johnsen, Hans E. [12 ]
Knudsen, Lene Meldgaard [4 ]
Linder, Olle [13 ]
Mellqvist, Ulf-Henrik [14 ]
Nesthus, Ingerid [15 ]
Nielsen, Johan Lanng [16 ]
机构
[1] Univ Hosp, Dept Hematol, S-22185 Lund, Sweden
[2] Linkoping Hosp, Dept Internal Med, Linkoping, Sweden
[3] Malmo Univ Hosp, Dept Hematol, Malmo, Sweden
[4] Rigshosp, Dept Hematol, Copenhagen, Denmark
[5] Ullevaal Univ Hosp, Dept Hematol, Oslo, Norway
[6] Univ Hosp, Dept Hematol, Linkoping, Sweden
[7] Univ Hosp, Dept Hematol, Uppsala, Sweden
[8] Univ Hosp, Dept Hematol, Odense, Denmark
[9] Univ Hosp, Dept Hematol, Tromso, Norway
[10] Norrland Univ Hosp, Dept Hematol, Umea, Sweden
[11] Univ Hosp, Dept Hematol, Trondheim, Norway
[12] Copenhagen Univ Hosp, Dept Hematol, Herlev, Denmark
[13] Univ Hosp, Dept Hematol, Orebro, Sweden
[14] Sahlgrens Univ Hosp, Dept Hematol, Gothenburg, Sweden
[15] Haukeland Hosp, Dept Hematol, Bergen, Norway
[16] Univ Hosp, Dept Hematol, Aarhus, Denmark
关键词
myeloma; transplantation; survival; response; relapse;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives. From 1994 to 1997 we conducted a population-based, prospective study on intensive therapy in newly diagnosed symptomatic myeloma patients younger than 60 years, comparing their survival to that of a conventionally treated historic population. Long-term results are presented, including the impact of the degree of response on survival and relapse pattern after transplantation. Design and Methods. The prospective population was formed of 397 patients and the historic population of 313 patients. Both populations were calculated to comprise more than 75% of the expected number of new cases. Results. After a median follow-up of 7 years survival was longer in the prospective population than in the historic one (median 60 versus 39 months; p=0.0002). When comparing only patients eligible for intensive therapy the median survival was 63 versus 44 months (p<0.0001). Attaining a complete response was associated with prolonged event-free survival but not overall survival. The pattern of relapse after transplantation was heterogeneous but could be divided into four major groups; insidious, classical, plasmacytoma form and transformed disease. The median survival after relapse was 29 months. The relapse pattern and time to relapse predicted outcome. Patients relapsing with an insidious or classical form of disease with skeletal events only, or after a long lasting first response were likely to respond well to conventional salvage therapy. In contrast, relapse with multiple symptoms, transformed disease or a short duration of first response implied bad prognosis. Interpretation and conclusions. The relapse pattern after autologous transplantation is heterogeneous and response to salvage therapy is variable. The degree of response and event-free survival after transplantation are not reliable surrogate markers for survival.
引用
收藏
页码:1228 / 1233
页数:6
相关论文
共 7 条
  • [1] Long-term survival (&gt; 10 years) of patients &gt; 60 years with induction therapy after cardiac transplantation
    Zuckermann, A
    Dunkler, D
    Deviatko, E
    Bodhjalian, A
    Czerny, M
    Ankersmit, J
    Wolner, E
    Grimm, M
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2003, 24 (02) : 283 - 291
  • [2] Long-Term Results of Prophylactic Donor Lymphocyte Infusions for Patients with Multiple Myeloma after Allogeneic Stem Cell Transplantation
    Groeger, Maximilian
    Gagelmann, Nico
    Wolschke, Christine
    von Pein, Ute-Marie
    Klyuchnikov, Evgeny
    Christopeit, Max
    Zander, Axel
    Ayuk, Francis
    Kroeger, Nicolaus
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (07) : 1399 - 1405
  • [3] Response to first-line chemotherapy and long-term survival in patients with multiple myeloma:: results of the MM87 prospective randomised protocol
    Riccardi, A
    Mora, O
    Tinelli, C
    Porta, C
    Danova, M
    Brugnatelli, S
    Grasso, D
    Tolcà, B
    Spanedda, R
    De Paoli, A
    Barbarano, L
    Cavanna, L
    Giordano, M
    Delfini, C
    Nicoletti, G
    Bergonzi, C
    Rinaldi, E
    Piccinini, L
    Ascari, E
    EUROPEAN JOURNAL OF CANCER, 2003, 39 (01) : 31 - 37
  • [4] Long-Term Results in Multiple Myeloma After High-Dose Melphalan and Autologous Transplantation According to Response Categories in the Era of Old Drugs
    Martino, Massimo
    Postorino, Maurizio
    Gallo, Giuseipe Alberto
    Messina, Giuseppe
    Neri, Santo
    Piro, Eugenio
    Gentile, Massimo
    Moscato, Tiziana
    Monteleone, Renza
    Fedele, Roberta
    Mazzone, Carla
    Console, Giuseppe
    Penna, Giuseppa
    Alati, Caterina
    Vincelli, Iolanda Donatella
    Irrera, Giuseppe
    Musolino, Caterina
    Ronco, Francesca
    Molica, Stefano
    Morabito, Fortunato
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (02) : 148 - 154
  • [5] Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem cell transplantation: long-term results from a single institution
    Tovar, Natalia
    Fernandez de Larrea, Carlos
    Arostegui, Juan I.
    Teresa Cibeira, Maria
    Rosinol, Laura
    Rovira, Montserrat
    Elena, Montserrat
    Filella, Xavier
    Yaguee, Jordi
    Blade, Joan
    HAEMATOLOGICA, 2013, 98 (07) : 1142 - 1146
  • [6] Multiple myeloma patients in long-term complete response after autologous stem cell transplantation express a particular immune signature with potential prognostic implication
    Arteche-Lopez, A.
    Kreutzman, A.
    Alegre, A.
    Sanz Martin, P.
    Aguado, B.
    Gonzalez-Pardo, M.
    Espino, M.
    Villar, L. M.
    Garcia Belmonte, D.
    de la Camara, R.
    Munoz-Calleja, C.
    BONE MARROW TRANSPLANTATION, 2017, 52 (06) : 832 - 838
  • [7] Predictive Factors of Survival After Thalidomide Therapy in Advanced Multiple Myeloma: Long-Term Follow-Up of a Prospective Multicenter Nonrandomized Phase II Study in 120 Patients
    Decaux, Olivier
    Renault, Alain
    Sebille, Veronique
    Moreau, Philippe
    Attal, Michel
    Voillat, Laurent
    Pegourie, Brigitte
    Tiab, Mourad
    Facon, Thierry
    Zerbib, Robert
    Grosbois, Bernard
    Bellissant, Eric
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2012, 12 (06) : 418 - 422